医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mannatech Declares Third Quarter 2022 Dividend

2022年11月11日 PM08:00
このエントリーをはてなブックマークに追加


 

FLOWER MOUND, Texas

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend of $0.20 per share of common stock, payable on Wednesday, December 28, 2022, to shareholders of record at the close of business on Wednesday, December 14, 2022. The dividend demonstrates a commitment to rewarding shareholders and encouraging long-term investment in Mannatech’s common stock.

Alfredo “Al” Bala, President and CEO of Mannatech, said, “Mannatech is fully committed to delivering value to our shareholders.”

About Mannatech

Mannatech, Incorporated is committed to transforming lives through the development of high quality integrated health, weight management, fitness and skin care products distributed through its global network of independent associates and members. The company has been operating for more than 25 years with operations in 25 markets^. For more information, visit Mannatech.com.

^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” “hope,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “potential,” and “continues” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, the outbreak of the novel coronavirus (“COVID-19″) pandemic, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006181/en/

CONTACT

Donna Giordano

Manager, Executive Office Administration

972-471-6512

ir@mannatech.com

www.mannatech.com

TimeLine:

同じカテゴリーの記事 

  • 继成功通过FDA检查后,KBI Biopharma续签并扩大了与全球领先制药公司的商业合同
  • BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s of Best Cure Pro Health and Medical Centers
  • Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics
  • AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
  • Rapid Medical™的主动进入解决方案获得美国FDA批准并在美完成首次神经血管病例治疗